G92.02
Immune effector cell-associated neurotoxicity syndrome, grade 2
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade 2
Medical Intelligence & Overview
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a neurological complication that can occur following treatments involving immune effector cells, such as CAR T-cell therapy. Specifically, Grade 2 ICANS reflects a moderate level of neurological symptoms that require medical monitoring and intervention. Recognized under ICD-10 code G92.02, this condition is an important consideration in patients undergoing advanced immunotherapies for cancer.
Causes & Symptoms
Clinical Causes: Administration of immune effector cell therapies like CAR T-cell therapy The activation of immune cells leading to cytokine release syndrome Inflammatory responses affecting the central nervous system Pre-existing neurological conditions that may predispose patients to neurotoxicity
Key Symptoms: Confusion or disorientation Difficulty concentrating Mild to moderate hallucinations Headache Fatigue Drowsiness or lethargy Mild speech difficulties Some motor weakness or tremors
Diagnostic & Treatment
Diagnosis Path: Diagnosis of Grade 2 ICANS involves clinical assessment based on neurological examinations and symptom evaluation. Healthcare providers monitor neurological signs, mental status, and cognitive functions. Imaging tests, such as MRI or CT scans, may be used to exclude other causes of neurological symptoms. Continuous observation is vital, as symptoms can progress or resolve with treatment adjustments.
Treatment Protocols: Managing Grade 2 ICANS primarily involves supportive care and addressing symptoms. Treatments may include:
Clinical Advice & FAQs
Billing Guidance
Is G92.02 a billable ICD-10 code?
Yes, G92.02 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.02?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade 2 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference